All vaccines being administered in Brazil are effective against Covid-19. This is what Fiocruz points out, in its first bulletin on the effectiveness of vaccines against the virus, released this Friday (10).
Called the Vigivac project, the study analyzed the four vaccines applied in Brazil from January to October this year and showed that all immunizing agents provide a great reduction in the risk of infections, hospitalizations and deaths as a result of Covid.
The survey was carried out from a database based on information from more than 150 million people who had completed the vaccination schedule 14 days ago.
In the age groups from 20 to 80 years, considering severe cases that required hospitalization, protection varied between 83% and 99% for all vaccines. In people under 60 years, all immunizers showed efficacy above 85% against the risk of hospitalization and above 89% for the risk of death.
The foundation listed the effectiveness for each type of vaccine available in the country.
Regarding AstraZeneca, the most used vaccine, the numbers were extremely positive. In the population aged up to 59 years, the immunizing agent was 99% effective against deaths.
However, the older the age group, the less effective the vaccine. In people aged 60 to 69 years, protection against the virus was 89% against hospitalizations and 97% against deaths.
In the group aged 70 to 79 years, protection against hospitalization was 84% and against deaths was 90%. While in individuals over 80 years of age, the Astrazeneca vaccine showed efficacy of 82% against hospitalizations and 91% against deaths.
In relation to Coronavac, among people aged 18 to 59 years, protection ranged from 89% to 95% in relation to deaths and from 85% to 91% for hospitalizations.
There was, according to Fiocruz, a significant drop in effectiveness in people over 60 years of age. In the age group 60 to 69 years, protection against severe forms of the disease was 81%, reaching 64% in people over 80 years of age.
According to Fiocruz, the Pfizer vaccine was also effective. In the population up to 59 years old, it was 99% for both deaths and hospitalizations.
The institute explained that this high rate can be explained by the fact that the vaccine was applied to the younger population “and at an epidemic time with less circulation of the virus, which may favor the effectiveness of the vaccine”.
As for Janssen’s immunizing agent, the study showed less protection in the population up to 59 years old, especially in relation to deaths.
Protection ranged from 78% to 94% against deaths and 88% and 91% against hospitalizations. In people aged 80 years and over, protection against death was 91%, and against hospitalization, 93%.
Data for the survey were collected from the Covid-19 National Vaccination Campaign (Covid-19 Vaccination); Flu Syndrome Notifications (e-SUS Notifies) and Severe Acute Respiratory Syndrome Notifications (SRAG 2020 and 2021; SIVEP-Influenza).
The study was coordinated by researcher Manoel Barral, from Fiocruz Bahia.
Reference: CNN Brasil